StemCellAtlas vets clinics and protocols against five criteria: regulatory compliance, outcome transparency, safety reporting, physician credentials, and patient independence. This methodology ensures recommendations meet evidence standards despite international variability.
Recommending a clinic to a patient is a serious responsibility. Unlike established healthcare, where accreditation and licensing are visible and enforceable, international stem cell clinics operate across variable regulatory regimes. A clinic legal and legitimate in Bulgaria might not meet FDA standards; conversely, a clinic unregulated in the US might exceed European safety standards. StemCellAtlas has developed a vetting framework to assess clinics consistently, regardless of home country.
The first criterion: regulatory compliance in the clinic's home jurisdiction. We require that the clinic operates legally under national healthcare law, holds appropriate licences, and is subject to health ministry oversight. This is not a guarantee of quality—many countries have loose oversight—but it confirms the clinic is not outright illegal or hiding. We verify clinic registration, check for regulatory warnings or enforcement actions, and confirm that healthcare professionals are licensed.
The second: outcome transparency. We require that the clinic publishes or provides aggregate outcome data: what percentage of patients improve, at what magnitude, over what duration, in which conditions. We look for adverse event reporting and honest acknowledgment of non-responders or complications. Clinics claiming 100% success rates are red-flagged. We assess outcome claims against published literature; if a clinic claims 95% success for Parkinson's treatment and literature supports 40%, the clinic is either treating a different population or overstating results.
The third: adverse event reporting. All medical interventions carry risks. We require clinics to maintain adverse event databases and report complications transparently. Clinics that claim zero adverse events across thousands of treatments are suspect; some complication rate is inevitable. We review reported adverse events for seriousness, follow-up care, and transparency in disclosure to patients.
The fourth: physician credentials. We verify that physicians performing procedures are trained in cell therapy, licensed in their home country, and ideally fellowship-trained or experienced (minimum 50 prior procedures). We check for criminal records, disciplinary actions, or loss of licensure. This is basic hygiene, but international verification is labour-intensive, and not all clinics cooperate fully.
The fifth: patient independence. We assess whether marketing materials feature genuine patient testimonials and independent platforms (Google Reviews, Doctoralia) with realistic review distributions, or whether testimonials are exclusively on the clinic's own website with perfect ratings. Independent negative reviews are actually a positive signal—they indicate the platform is genuine and not filtered. We also verify that patients can contact other patients through independent means (patient support groups, forums) to hear unfiltered experiences.
Beyond vetting, we assess alignment with evidence. Does the clinic's protocol match published best-practice literature? Are they using established techniques (autologous mesenchymal cells, bone marrow or fat-derived) or experimental methods (pluripotent cells, genetically modified cells) with less foundation? Are follow-up protocols evidence-based?
For emerging protocols (exosome therapy, neural stem cells), the bar is lower because evidence itself is nascent. But we require clear informed consent that treatment is investigational, transparent outcome tracking, and realistic honesty about what is proven versus hoped-for.
We exclude clinics that: claim cures for progressive diseases; advertise unproven applications (Alzheimer's without trial context); offer multiple unrelated therapies suggesting marketing-driven breadth; demand large advance payments without refund policies; or operate under multiple brands in different countries (suggesting reputation evasion).
The goal is not to identify perfect clinics—none exist—but to identify clinics where a patient's basic safety and honest information-provision are likely. Within that cohort, patients make informed choices based on cost, location, specific protocol fit, and personal preferences.
Educational content; outcomes vary by patient and most uses are investigational — consult a physician. Reviewed by the StemCellAtlas editorial team.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם